Immunotec Medical Corporation announced a clinical development program in the prevention of wasting in cancer

Montreal (Quebec) - October 20th 2003 - Immunotec Medical Corporation announced today that a Clinical Trial Application (CTA) has been approved in Canada for a Phase 2 clinical trial to study the efficacy of IMN 1207 (a soluble protein based formulation) in the prevention of cachexia (wasting) in colorectal or non small cell lung cancer.

About the Trial

This multi-centre, randomized, placebo controlled double-blind Phase 2 trial will evaluate the safety and efficacy of IMN 1207 in the prevention of wasting over a six month period in 74 patients, during or following, chemotherapy, radiation or surgery in the treatment of colorectal or non-small cell lung cancer. The trial will be conducted at number of prominent university hospital cancer centres across Canada including the McGill Department of Oncology, the Hamilton Regional Cancer Centre and the Cross Cancer Institute in Edmonton Alberta.

About Cachexia (Wasting)

About half of cancer patients experience wasting (cachexia) that is characterized by progressive and substantial involuntary weight loss. 1 It results from the gradual depletion of host body cell mass (bcm), with loss of adipose tissue and skeletal muscle mass that may reach as high as 80%. 2 Low body cell mass (bcm) is associated with low performance status and has been clearly linked to significantly reduced survival in certain cancers and in other diseases such as AIDS3-6. Wasting contributes to deterioration of quality of life, and increased morbidity and mortality in

cancer patients\textsuperscript{7}. Since wasting is an important determinant of performance status and survival in cancer, it is an important key target for therapeutic intervention.

About Immunotec Medical Corporation

Immunotec Medical Corporation is focused on the development and commercialization of innovative therapeutics for cancer management. Immunotec Medical Corporation is a subsidiary of Immunotec Research Limited, a privately held company based in Vaudreuil-Dorion, Quebec Canada.

For more information, please contact:
John H. Molson
Vice-President, Research & Development
Tel: (450) 424-9992, ext. 234